![]() ![]() The more LDL-C is reduced on statin therapy, the greater will be subsequent risk reduction. In patients with clinical ASCVD, reduce low-density lipoprotein cholesterol (LDL-C) with high-intensity statin therapy or maximally tolerated statin therapy. In all age groups, lifestyle therapy is the primary intervention for metabolic syndrome. 6) and emphasizes intensive lifestyle efforts. In young adults 20 to 39 years of age, an assessment of lifetime risk facilitates the clinician–patient risk discussion (see No. In younger individuals, healthy lifestyle can reduce development of risk factors and is the foundation of ASCVD risk reduction. A healthy lifestyle reduces atherosclerotic cardiovascular disease (ASCVD) risk at all ages. In all individuals, emphasize a heart-healthy lifestyle across the life course. Top 10 Take-Home Messages to Reduce Risk of Atherosclerotic Cardiovascular Disease Through Cholesterol Management Prognostic Significance of CAC e1123Īppendix 1: Author Relationships With Industry and Other Entities (Relevant)-2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (August 2018) e1139Īppendix 2: Reviewer Relationships With Industry and Other Entities (Comprehensive)-2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (August 2018) e1141 Monitoring and Adjustment of Treatment e1123Ĩ.2.5. Refinement of Clinician–Patient Risk Discussion e1123Ĩ.2.4. Improvement in Lifetime Risk Estimate e1123Ĩ.2.3. Economic Value Considerations: PCSK9 Inhibitors e1121Ĩ.2.1. Statin Safety and Statin-Associated Side Effects e1117ħ.1. Primary Prevention in Other Age Groups e1107ĥ. Monitoring in Response to LDL-C–Lowering Therapy e1106Ĥ.4.4. Primary Prevention Adults 40 to 75 Years of Age With LDL-C Levels 70 to 189 mg/dL (1.7 to 4.8 mmol/L) e1102Ĥ.4.3. Evaluation and Risk Assessment e1099Ĥ.4.2. Severe Hypercholesterolemia (LDL-C ≥190 mg/dL ) e1095Ĥ.4.1. Nonstatin Add-on Drugs to Statin Therapy e1091Ĥ.2. ![]() Lifestyle Therapies and Metabolic Syndrome e1090ģ.2.3. Diet Composition, Weight Control, and Physical Activity e1090ģ.1.2. Monitoring Response of LDL-C to Statin Therapy e1090ģ.1.1. Measurements of Apolipoprotein B and Lipoprotein (a) e1089Ģ.4. Measurements of LDL-C and Non–HDL-C e1088Ģ.3. Cholesterol, LDL-C, and ASCVD e1087Ģ.1.3. Cholesterol, Lipoproteins, and Apolipoprotein B e1087Ģ.1.2. Serum Cholesterol, Lipoproteins, and ASCVD e1087Ģ.1.1. High Blood Cholesterol and ASCVD e1087Ģ.1. Class of Recommendation and Level of Evidence e1087Ģ. Organization of the Writing Committee e1086ġ.5. Methodology and Evidence Review e1085ġ.2. Top 10 Take-Home Messages to Reduce Risk of Atherosclerotic Cardiovascular Disease Through Cholesterol Management e1083ġ.1. Customer Service and Ordering InformationĢ018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Stroke: Vascular and Interventional Neurology.Journal of the American Heart Association (JAHA).Circ: Cardiovascular Quality & Outcomes.Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |